Statement from Anthony Castore and AlchemIQ on the Bioglutide / Biomed Situation

Every industry has defining moments the ones that separate hype from principle and reveal who’s truly here for the long game. This is one of those moments for ours, and I want to be completely transparent about where we stand.

Biomed Industries is the company credited with discovering Bioglutide (NA-931) and developing it as a next-generation GLP-based compound. Our raw materials came from the same supplier Biomed reportedly uses. Recently, serious accusations have surfaced against Biomed claims of fraudulent data, lack of publicly verifiable sequence information, and the absence of a disclosed CAS number or molecular structure. The accuser has raised valid scientific concerns that deserve to be addressed. At the same time, these allegations are new, and Biomed has not yet had the opportunity to publicly respond. That’s why we are pausing not panicking.

Even in moments like this, our safeguards remain strong. We can fully document purity through HPLC and LC-MS, confirm sterility and endotoxin levels, and provide verified Certificates of Analysis. However, without a public reference structure or sequence, no lab including ours can confirm 100% molecular identity. We can verify that a compound is clean, sterile, and potent, but we can’t compare it to a molecule that’s never been fully published.

To give some context, CB4211 is a great example of how innovation often moves faster than public documentation. This compound, developed for mitochondrial health and metabolic optimization, has been prescribed by physicians and compounded by pharmacies despite its structure, sequence, and CAS never being publicly released. That doesn’t make it ineffective or illegitimate it simply illustrates that, just like Bioglutide, the available data can only go so far. In both cases, these products are sourced, tested, and manufactured to the highest standards, with thorough purity and safety testing but without full structural transparency. That means identity and uniqueness are established through trust, testing, and outcomes rather than public disclosure. For all we know, CB4211 could be a more advanced form or reformulated analog of MOTS-c—or perhaps just a more expensive version under a new label. Until formal sequencing or patent releases are made public, no one can say for sure. This doesn’t discredit its value; it simply reminds us that in early-stage biotech, certainty often trails behind discovery. That’s why rigorous testing, ethical sourcing, and open communication about what is known and what isn’t are so vital.

Here’s what we’re doing next: All Bioglutide sales are temporarily paused while we conduct independent sequencing and mass spectrometry on our inventory. We’ve engaged third-party certified labs to verify structure, purity, and stability. Once results are complete, we’ll publish all data CoAs, sterility, toxin testing, everything for full transparency. Anyone who feels uncertain can receive a full credit toward a future purchase, no questions asked. If Biomed later releases verified data, we’ll compare our findings directly to theirs to ensure full alignment. We’ve had only positive reports from clients using our Bioglutide so far, but integrity requires we lead with verification, not assumption.

The broader reality is that the GLP-agonist field is fiercely competitive, and early innovators often face intense resistance. History shows that when smaller biotech firms begin to threaten established players, sudden accusations, lawsuits, and smear campaigns tend to appear. While we take these scientific questions seriously, it’s also fair to ask whether some of this noise is strategic—designed to devalue Biomed, drain their resources, and make it easier for a larger firm to acquire their IP for pennies on the dollar. We’re not speculating we’re staying objective but we’re also not blind to how this industry sometimes works.

For us, this isn’t just a challenge it’s an opportunity to show what real leadership looks like. It’s easy to lead when things are smooth; it’s character-defining when the ground shifts. At AlchemIQ Labs, our mission has always been to lead innovation from a foundation of integrity. We don’t chase trends we build truths. When uncertainty arises, you can trust that we will slow down when others rush, verify when others speculate, and always put people before profit. That’s how innovation earns its longevity.

Every compound, every decision, every risk we take is grounded in two principles: scientific rigor and human trust. This moment doesn’t define us it reveals us. And it reinforces what I want every client, athlete, and clinician to know: you can always count on us to lead at the top of innovation without compromising integrity at the core.

We’ll keep you informed as results come in we’re just as eager as you are for clarity. We won’t be the company that keeps a questionable product on shelves because of sunk costs, and we won’t chase attention with reckless dosing or sensational marketing. Sadly, our space has its share of big personalities who care more about spotlight and sales than truth or safety. We choose a different path one rooted in curiosity, humility, and accountability. We’re not here for the headlines; we’re here for the long game of discovery and health.

We make products we believe in and are willing to use ourselves but that doesn’t mean we’ll always get it perfect. We’d rather sit with thousands of dollars in unusable product than break the trust of the people who count on us. When it comes to your health and your outcomes, align yourself with those who reflect your values—because in this industry, character matters just as much as chemistry.

Thank you for trusting us to lead from the front and to do it the right way.

— Anthony CastoreSSRP Fellow • Strength Coach • Founder, Castore Core Intelligence / AlchemIQ Labs

32 comments